NLRP3 and colitis: Wogonoside, as the glucuronide metabolite of wogonin, at dosages of 12.5, 25 or 50 mg/kg intragastrically, protects against DSS‐induced experimental colitis in mice by inhibiting NF‐κB and NLRP3 inflammasome activation 35.